Brandes Investment Partners LP trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,764 shares of the biotechnology company’s stock after selling 1,011 shares during the period. Brandes Investment Partners LP owned about 0.07% of United Therapeutics worth $3,678,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in United Therapeutics by 2.8% during the first quarter. Principal Financial Group Inc. now owns 196,233 shares of the biotechnology company’s stock valued at $22,049,000 after buying an additional 5,396 shares during the period. State of Alaska Department of Revenue boosted its stake in United Therapeutics by 40.1% during the second quarter. State of Alaska Department of Revenue now owns 4,720 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 1,350 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in United Therapeutics by 10.6% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 14,941 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 1,437 shares during the period. Bank of Montreal Can bought a new stake in United Therapeutics during the second quarter valued at $7,258,000. Finally, Fox Run Management L.L.C. bought a new stake in United Therapeutics during the second quarter valued at $269,000. 93.69% of the stock is currently owned by hedge funds and other institutional investors.

UTHR has been the subject of several research analyst reports. Wedbush lifted their price objective on United Therapeutics from $234.00 to $253.00 and gave the company an “outperform” rating in a research note on Thursday, August 2nd. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $118.00 to $126.00 and gave the company a “neutral” rating in a research note on Friday, November 2nd. Standpoint Research raised United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Cowen set a $106.00 price target on United Therapeutics and gave the company a “hold” rating in a research report on Thursday, November 15th. Finally, BidaskClub upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. United Therapeutics presently has an average rating of “Hold” and a consensus target price of $136.50.

NASDAQ UTHR opened at $113.22 on Wednesday. United Therapeutics Co. has a twelve month low of $100.57 and a twelve month high of $152.55. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09. The stock has a market cap of $5.30 billion, a price-to-earnings ratio of 10.40, a PEG ratio of 28.36 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm had revenue of $412.70 million for the quarter, compared to analysts’ expectations of $378.22 million. During the same quarter in the previous year, the business earned $4.69 EPS. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. On average, analysts predict that United Therapeutics Co. will post 14.28 EPS for the current fiscal year.

In other United Therapeutics news, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $119.00, for a total transaction of $96,390.00. Following the sale, the director now owns 1,555 shares in the company, valued at $185,045. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.20% of the company’s stock.

WARNING: “Brandes Investment Partners LP Sells 1,011 Shares of United Therapeutics Co. (UTHR)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/11/21/brandes-investment-partners-lp-sells-1011-shares-of-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Article: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.